Renal denervation in patients with chronic kidney disease: current evidence and future perspectives
Open accessThe DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.
Abstract
Supported by several high-quality randomized controlled trials and registry analyses, catheter-based renal denervation is becoming an important adjunctive treatment modality for the safe and efficacious treatment of hypertension besides lifestyle modifications and antihypertensive medication. Renal denervation is of particular interest to nephrologists as the intervention may provide additional benefits to hypertensive people with chronic kidney disease (CKD), a condition typically characterized by sympathetic hyperactivity. A growing body of clinical evidence supports the safety and efficacy of renal denervation in this difficult-to-control population. In addition, preclinical and clinical research works indicate potential nephroprotective effects in CKD patients. The current review examines recent research on renal denervation with a focus on renal disease and assesses the latest findings and their implications from a nephrologist's perspective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![FIGURE 1: Effect of bilateral nephrectomy on SNS activity in renal transplant patients. From Hausberg et al [12]. MSNA, muscle sympathetic activity; CVR, calf vascular resistance; n.s., not significant.](https://figures.cochat.ai/paper-figures/ebf935d0df6749fe90c2ea67d30ad069/renal-denervation-in-patients-with-chronic-kidney-disease-current-evidence-and-figure-1.jpg)

![FIGURE 3: Changes from baseline with renal denervation or sham up to 36 months in the randomized, sham-controlled SPYRAL-ON MED study. Medication changes were allowed after end of primary follow-up at 6 months and patients were unblinded to randomization status at 12 months. Adapted from Mahfoud et al [27].](https://figures.cochat.ai/paper-figures/afc12b7691ca453993712996b741cff9/renal-denervation-in-patients-with-chronic-kidney-disease-current-evidence-and-figure-3.jpg)
![FIGURE 4: Muscle sympathetic nerve activity (MSNA) expressed as burst frequency (bs/min; blue bars; left-hand scale) and burst incidence (bs/100 heartbeats; green bars; right-hand scale) in patients and healthy individuals grouped according to progressively more severe degrees of renal dysfunction. Adapted from Grassi et al [43].](https://figures.cochat.ai/paper-figures/718d520b7d7942d49274119fde9a8c14/renal-denervation-in-patients-with-chronic-kidney-disease-current-evidence-and-figure-4.jpg)
![FIGURE 5: Mean basal total urinary NOx (nitrate + nitrite) excretion (V) in normotensive (control) and hypertensive sheep with CKD 2 and 30 months after renal denervation or sham procedures, respectively. Lines indicate standard error. *P < .05 comparing sham groups at follow-up. ##P < .05, ####P < .0001 comparing sham and treated groups at follow-up. From Singh et al [58].](https://figures.cochat.ai/paper-figures/0425e9ce69d2475d9ef8ec20b2f7a4bd/renal-denervation-in-patients-with-chronic-kidney-disease-current-evidence-and-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As large clinical trials of RDN have excluded patients with GFR <45 ml/min/1.73 m2 (ref. 119), the efficacy of this approach in patients with kidney failure is difficult to discern.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Self-citationBikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
A Controlled Trial of Renal Denervation for Resistant Hypertension
Bhatt, D. L., Kandzari, D. E., O'Neill, W. W., D'Agostino, R., Flack, J. M., Katzen, B. T., Leon, M. B., Liu, M., Mauri, L., Negoita, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402670 · Cited by 2,186
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132 · cited 2×
“This increase in GFR was accompanied by a sustained reduction in MAP; conversely there was a continual increase in MAP with time in sham-treated sheep.”
BackgroundKandzari, D. E., Böhm, M., Mahfoud, F., Townsend, R. R., Weber, M. A., Pocock, S., Tsioufis, K., Tousoulis, D., Choi, J. W., East, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30951-6 · Cited by 793
Self-citationTownsend, R. R., Mahfoud, F., Kandzari, D. E., Kario, K., Pocock, S., Weber, M. A., Ewen, S., Tsioufis, K., Tousoulis, D., Sharp, A. S. P., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32281-x · Cited by 752
Self-citationAzizi, M., Schmieder, R. E., Mahfoud, F., Weber, M. A., Daemen, J., Davies, J., Basile, J., Kirtane, A. J., Wang, Y., Lobo, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31082-1 · Cited by 740
Self-citationBöhm, M., Kario, K., Kandzari, D. E., Mahfoud, F., Weber, M. A., Schmieder, R. E., Tsioufis, K., Pocock, S., Konstantinidis, D., Choi, J. W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30554-7 · Cited by 606
Self-citationPredictors of blood pressure response in the SYMPLICITY HTN-3 trial
Kandzari, D. E., Bhatt, D. L., Brar, S., Devireddy, C. M., Esler, M., Fahy, M., Flack, J. M., Katzen, B. T., Lea, J., Lee, D. P., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu441 · Cited by 546 · cited 1×
“The latter two confounders would explain the substantial BP reductions in the sham group [17, 18].”
BackgroundZoccali, C., Mallamaci, F., Parlongo, S., Cutrupi, S., Benedetto, F. A., Tripepi, G., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., et al. (2002) · Circulation · doi:10.1161/hc1102.105261 · Cited by 519 · cited 1×
“independent predictor of mortality as well as fatal and nonfatal CV events in patients undergoing haemodialysis [10].”
BackgroundSympathetic Nerve Activity in End-Stage Renal Disease
Hausberg, M., Kosch, M., Harmelink, P., Barenbrock, M., Hohage, H., Kisters, K., Dietl, K. H., & Rahn, K. H. (2002) · Circulation · doi:10.1161/01.cir.0000034043.16664.96 · Cited by 493
Azizi, M., Sanghvi, K., Saxena, M., Gosse, P., Reilly, J. P., Levy, T., Rump, L. C., Persu, A., Basile, J., Bloch, M. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00788-1 · Cited by 439 · cited 1×
“Notably, two controlled trials in patients with resistant hypertension and high medication burden, the prospective, randomized, open-label blinded endpoint DENERHTN [26] and the two multicentre, single-blind, sham-controlled trials RADIANCE-HTN TRIO [24] and SPYRAL HTN-ON MED [27] have found that adherence to antihype…”
BackgroundSelf-citationMuntner, P., Anderson, A., Charleston, J., Chen, Z., Ford, V., Makos, G., O'Connor, A., Perumal, K., Rahman, M., Steigerwalt, S., et al. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.09.014 · Cited by 423
Strippoli, G. F. M., Craig, M., Deeks, J. J., Schena, F. P., & Craig, J. C. (2004) · BMJ · doi:10.1136/bmj.38237.585000.7c · Cited by 385
Hering, D., Lambert, E. A., Marusic, P., Walton, A. S., Krum, H., Lambert, G. W., Esler, M. D., & Schlaich, M. P. (2013) · Hypertension · doi:10.1161/hypertensionaha.111.00194 · Cited by 356
Mahfoud, F., Kandzari, D. E., Kario, K., Townsend, R. R., Weber, M. A., Schmieder, R. E., Tsioufis, K., Pocock, S., Dimitriadis, K., Choi, J. W., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00455-x · Cited by 295 · cited 6×
“Threeyear follow-up data from SPYRAL-ON MED were recently published [27].”
BackgroundInfluentialSelf-citationSim, J. J., Bhandari, S. K., Shi, J., Reynolds, K., Calhoun, D. A., Kalantar-Zadeh, K., & Jacobsen, S. J. (2015) · Kidney International · doi:10.1038/ki.2015.142 · Cited by 238 · cited 1×
“In a vicious feedback loop, the presence of hypertension drives CKD severity: uncontrolled resistant hypertension is associated with a marked increase in the risk of developing the end-stage renal disease (ESRD) over a 5-year period [2].”
BackgroundNeural control of the kidney: functionally specific renal sympathetic nerve fibers
DiBona, G. F. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.279.5.r1517 · Cited by 228 · cited 1×
“Efferent nerve activation reduces renal blood flow and urinary excretion of salt and water, and increases renin release from the kidney, with the effect of increasing BP [8].”
BackgroundCarey, R. M., Sakhuja, S., Calhoun, D. A., Whelton, P. K., & Muntner, P. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12191 · Cited by 218
Thomas, G., Xie, D., Chen, H.-Y., Anderson, A. H., Appel, L. J., Bodana, S., Brecklin, C. S., Drawz, P., Flack, J. M., Miller, E. R., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06487 · Cited by 190
Mahfoud, F., Böhm, M., Azizi, M., Pathak, A., Durand Zaleski, I., Ewen, S., Tsioufis, K., Andersson, B., Blankestijn, P. J., Burnier, M., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv192 · Cited by 177 · cited 1×
“The latter two confounders would explain the substantial BP reductions in the sham group [17, 18].”
BackgroundSelf-citationCatheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety
Rippy, M. K., Zarins, D., Barman, N. C., Wu, A., Duncan, K. L., & Zarins, C. K. (2011) · Clinical Research in Cardiology · doi:10.1007/s00392-011-0346-8 · Cited by 173 · cited 1×
“However, the short-term risk from renal denervation has been shown to be limited: damaged endothelium recovers within a week [48], the arterial wall and soft tissue within 6 months [49].”
BackgroundBooth, L. C., Nishi, E. E., Yao, S. T., Ramchandra, R., Lambert, G. W., Schlaich, M. P., & May, C. N. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04176 · Cited by 171 · cited 1×
“A study in normotensive sheep in 2015 found no morphologically functional nerve regeneration 11 months after renal denervation, but the authors noted recovered functional afferent and efferent responses to electric stimulation [32].”
BackgroundFunction of Renal Nerves in Kidney Physiology and Pathophysiology
Osborn, J. W., Tyshynsky, R., & Vulchanova, L. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-091656 · Cited by 171 · cited 1×
“The above findings support the potential for renal denervation to achieve the dual effect of reducing efferent and afferent nerve activity, moderating the direct effect of renal signalling on BP and the indirect effect of afferent signalling on brain sympathetic activity outflow [15].”
BackgroundAzizi, M., Pereira, H., Hamdidouche, I., Gosse, P., Monge, M., Bobrie, G., Delsart, P., Mounier-Véhier, C., Courand, P.-Y., Lantelme, P., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.022922 · Cited by 152 · cited 1×
“Notably, two controlled trials in patients with resistant hypertension and high medication burden, the prospective, randomized, open-label blinded endpoint DENERHTN [26] and the two multicentre, single-blind, sham-controlled trials RADIANCE-HTN TRIO [24] and SPYRAL HTN-ON MED [27] have found that adherence to antihype…”
BackgroundDiagnosis and treatment of arterial hypertension 2021
Ott, C., & Schmieder, R. E. (2021) · Kidney International · doi:10.1016/j.kint.2021.09.026 · Cited by 151 · cited 1×
“In contrast to drugs, which must be taken regularly and possibly for life, renal denervation is considered a single intervention [31].”
BackgroundSelf-citationKario, K., Yokoi, Y., Okamura, K., Fujihara, M., Ogoyama, Y., Yamamoto, E., Urata, H., Cho, J.-M., Kim, C.-J., Choi, S.-H., et al. (2022) · Hypertension Research · doi:10.1038/s41440-021-00754-7 · Cited by 143 · cited 2×
“A number of confounders were identified: lack of standardized medications, incomplete medication blinding of treating physicians and coordinators, and lack of objective measurement of adherence [19, 20].”
BackgroundEuropean Society of Hypertension position paper on renal denervation 2021
Schmieder, R. E., Mahfoud, F., Mancia, G., Azizi, M., Böhm, M., Dimitriadis, K., Kario, K., Kroon, A. A., D Lobo, M., Ott, C., et al. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002933 · Cited by 131 · cited 2×
“Renal denervation is becoming a relevant treatment option for hypertension, as confirmed by the latest position statements and consensus documents from international [5, 6, 64] and national societies.”
BackgroundSelf-citationOtt, C., Mahfoud, F., Schmid, A., Toennes, S. W., Ewen, S., Ditting, T., Veelken, R., Ukena, C., Uder, M., Böhm, M., et al. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000556 · Cited by 129 · cited 2×
“73 m2 to be attenuated over at least 12 months by renal denervation [61].”
BackgroundSelf-citationTownsend, R. R., Walton, A., Hettrick, D. A., Hickey, G. L., Weil, J., Sharp, A. S. P., Blankenstijn, P. J., Böhm, M., & Mancia, G. (2020) · EuroIntervention · doi:10.4244/eij-d-19-00902 · Cited by 122 · cited 2×
“20 annual incidence of renal artery stenting following RF renal denervation [50].”
BackgroundMethodRenal Denervation in High-Risk Patients With Hypertension
Mahfoud, F., Mancia, G., Schmieder, R., Narkiewicz, K., Ruilope, L., Schlaich, M., Whitbourn, R., Zirlik, A., Zeller, T., Stawowy, P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.036 · Cited by 121
Self-citationChanges in Plasma Renin Activity After Renal Artery Sympathetic Denervation
Mahfoud, F., Townsend, R. R., Kandzari, D. E., Kario, K., Schmieder, R. E., Tsioufis, K., Pocock, S., David, S., Patel, K., Rao, A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.044 · Cited by 115 · cited 1×
“A relevant selection criterion for renal-denervation candidates may be high sympathetic activity accompanying elevated BP [41].”
BackgroundSelf-citationSTROJEK, K., GRZESZCZAK, W., GÓRSKA, J., LESCHINGER, M. I., & RITZ, E. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v123602 · Cited by 112
Mahfoud, F., Renkin, J., Sievert, H., Bertog, S., Ewen, S., Böhm, M., Lengelé, J.-P., Wojakowski, W., Schmieder, R., van der Giet, M., et al. (2020) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.10.048 · Cited by 106
Self-citationThe Transplanted Human Kidney Does Not Achieve Functional Reinnervation
Hansen, J. M., Abildgaard, U., Fogh-Andersen, N., Kanstrup, I.-L., Bratholm, P., Plum, I., & Strandgaard, S. (1994) · Clinical Science · doi:10.1042/cs0870013 · Cited by 87 · cited 1×
“However, the transplanted human kidney does not achieve functional reinnervation [36] and according to our current knowledge, the same appears to be true for denervated kidneys.”
BackgroundSingh, R. R., McArdle, Z. M., Iudica, M., Easton, L. K., Booth, L. C., May, C. N., Parkington, H. C., Lombardo, P., Head, G. A., Lambert, G., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12250 · Cited by 86 · cited 1×
“from normotensive models may be of limited relevance to clinical renal denervation for hypertension [33].”
BackgroundSham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients With Hypertension
Sardar, P., Bhatt, D. L., Kirtane, A. J., Kennedy, K. F., Chatterjee, S., Giri, J., Soukas, P. A., White, W. B., Parikh, S. A., & Aronow, H. D. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.12.082 · Cited by 86 · cited 1×
“A metaanalysis in 2019 of 977 patients from six trials found no significant difference between intervention and sham in the changes from baseline in eGFR, either in first- or secondgeneration trials [51].”
BackgroundWeber, M. A., Kirtane, A. J., Weir, M. R., Radhakrishnan, J., Das, T., Berk, M., Mendelsohn, F., Bouchard, A., Larrain, G., Haase, M., et al. (2020) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.10.061 · Cited by 86
Desir, G. V. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f521ba · Cited by 79 · cited 1×
“As renalase degrades catecholamines the reduced activity exposes the kidney to increased levels of these molecules, with associated adverse effects on BP and cardiac function [44].”
BackgroundEffect of renal denervation on kidney function in patients with chronic kidney disease
Hering, D., Marusic, P., Duval, J., Sata, Y., Head, G. A., Denton, K. M., Burrows, S., Walton, A. S., Esler, M. D., & Schlaich, M. P. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.01.047 · Cited by 77 · cited 1×
“Similar stabilisation of eGFR for up to 24 months after the intervention were shown in 46 patients with CKD Stage 3 [62].”
MethodKandzari, D. E., Mahfoud, F., Weber, M. A., Townsend, R., Parati, G., Fisher, N. D. L., Lobo, M. D., Bloch, M., Böhm, M., Sharp, A. S. P., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057687 · Cited by 76 · cited 1×
“Renal denervation is becoming a relevant treatment option for hypertension, as confirmed by the latest position statements and consensus documents from international [5, 6, 64] and national societies.”
BackgroundSelf-citationGrassi, G. M., Biffi, A., Seravalle, G., Bertoli, S. V., Airoldi, F., Corrao, G., Pisano, A., Mallamaci, F., Mancia, G., & Zoccali, C. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002661 · Cited by 75
Grassi, G., Seravalle, G., Brambilla, G., Trabattoni, D., Cuspidi, C., Corso, R., Pieruzzi, F., Genovesi, S., Stella, A., Facchetti, R., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04823 · Cited by 74 · cited 1×
“MSNA, reflecting the systemic sympathetic activity, has also been shown to be significantly reduced after renal denervation in humans with hypertension [13].”
BackgroundRenal safety of catheter-based renal denervation: systematic review and meta-analysis
Sanders, M. F., Reitsma, J. B., Morpey, M., Gremmels, H., Bots, M. L., Pisano, A., Bolignano, D., Zoccali, C., & Blankestijn, P. J. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx088 · Cited by 73 · cited 1×
“Sanders [52] analysed 2381 patients for whom data were available in 2017 and found no statistically significant change in eGFR after on average 9.”
MethodOtt, C., Mahfoud, F., Mancia, G., Narkiewicz, K., Ruilope, L. M., Fahy, M., Schlaich, M. P., Böhm, M., & Schmieder, R. E. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab154 · Cited by 62 · cited 4×
“In the Global Symplicity Registry, the largest cohort followed currently, reductions in both office and ambulatory BP have been sustained over a 3-year period [37].”
BackgroundInfluentialSelf-citationKiuchi, M. G., Graciano, M. L., Carreira, M. A. M. D. Q., Kiuchi, T., Chen, S., & Lugon, J. R. (2016) · The Journal of Clinical Hypertension · doi:10.1111/jch.12724 · Cited by 61 · cited 1×
“73m2) and refractory hypertension, eGFR even increased from baseline after renal denervation and the difference remained significant at all time points up to the end of follow-up at 24 months [63].”
BackgroundOgoyama, Y., Tada, K., Abe, M., Nanto, S., Shibata, H., Mukoyama, M., Kai, H., Arima, H., & Kario, K. (2022) · Hypertension Research · doi:10.1038/s41440-021-00761-8 · Cited by 59 · cited 1×
“This was recently confirmed in a metaanalysis of nine trials and 1555 patients undergoing renal denervation or sham [30].”
ResultSakakura, K., Tunev, S. S., Yahagi, K., O’Brien, A. J., Ladich, E. R., Kolodgie, F. D., Melder, R. J., Joner, M., & Virmani, R. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.001813 · Cited by 56 · cited 1×
“However, the short-term risk from renal denervation has been shown to be limited: damaged endothelium recovers within a week [48], the arterial wall and soft tissue within 6 months [49].”
BackgroundSGLT-2 inhibitors and nephroprotection: current evidence and future perspectives
Piperidou, A., Loutradis, C., & Sarafidis, P. A. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-00393-4 · Cited by 51 · cited 1×
“Accumulated evidence supports a nephroprotective effect from angiotensinreceptor blockers (ARBs) and sodium-glucose co-transporter2 (SLGT2) inhibitors [55, 56].”
BackgroundKandzari, D. E., Townsend, R. R., Bakris, G. L., Basile, J., Bloch, M. J., Cohen, D. L., East, C. A., Ferdinand, K. C., Fisher, N. D. L., Kirtane, A. J., et al. (2021) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29884 · Cited by 49 · cited 5×
“physician inertia, patient non-adherence, lack of social support, depression and the complexity of polypharmacy regimens inmore severe cases of hypertension [5].”
BackgroundInfluentialXia, M., Liu, T., Chen, D., & Huang, Y. (2021) · International Journal of Hyperthermia · doi:10.1080/02656736.2021.1916100 · Cited by 41 · cited 1×
“The renal denervation procedure is effective in hypertensive patients with CKD: in the meta-analysis in 2021 of single-centre studies on patients with CKD [45], office BP and 24-h ambulatory BP were significantly reduced from baseline to 1 month (P < .”
BackgroundRenal denervation: where do we stand and what is the relevance to the nephrologist?
Schmieder, R. E. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa237 · Cited by 37
Self-citationMauriello, A., Rovella, V., Anemona, L., Servadei, F., Giannini, E., Bove, P., Anselmo, A., Melino, G., & Daniele, N. D. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002426 · Cited by 33 · cited 1×
“A significant increase in nerve endings in the internal area of renal artery adventitia has been found in patients with ESRD on haemodialysis, compared with patients with less severe CKD or normal renal function [42].”
Rousselle, S. D., Brants, I. K., Sakaoka, A., Hubbard, B. S., Jackson, N. D., Wicks, J. R., Dillon, K. N., Naiche, L. A., Hart, R., Garza, J. A., et al. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.002293 · Cited by 33 · cited 1×
“There is good evidence fromnormotensive porcinemodels that a progressive regenerative response may occur as early as 7 days after renal denervation [34], but immunohistochemical observations have identified prominent fibrotic infiltration at the site of procedural injury, which attenuates the original delineation of t…”
BackgroundSchneider, S., Promny, D., Sinnecker, D., Byrne, R. A., Müller, A., Dommasch, M., Wildenauer, A., Schmidt, G. P., Heemann, U. W., Laugwitz, K., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv311 · Cited by 31 · cited 1×
“A small randomized study in renal transplant recipients indicated that the intervention is also effective and safe in this population [47].”
BackgroundImpaired basal NO activity in patients with glomerular disease and the influence of oxidative stress
Schäufele, T. G., Schlaich, M. P., Delles, C., Klingbeil, A. U., Fleischmann, E. H., & Schmieder, R. E. (2006) · Kidney International · doi:10.1038/sj.ki.5001745 · Cited by 25 · cited 1×
“This is at least in part due to increased oxidative stress in the renal vasculature [59].”
BackgroundSelf-citationNephroprotection by Antihypertensive Agents
Schmieder, R. E. (1994) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199406242-00009 · Cited by 22 · cited 1×
“It has long been discussed whether there is an additional effect from antihypertensive treatments beyond reducing the risk of kidney damage associated with high BP [54].”
BackgroundSelf-citationSingh, R. R., McArdle, Z. M., Booth, L. C., May, C. N., Head, G. A., Moritz, K. M., Schlaich, M. P., & Denton, K. M. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16718 · Cited by 15
Kiuchi, M. G., & Chen, S. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.08.262 · Cited by 14 · cited 1×
“CKD [60], which is in line with the reported greater effects in CKD sheep than in normotensive animals.”
ResultLong-Term Effects of Renal Artery Denervation
Juknevičius, V., Berūkštis, A., Juknevičienė, R., Jasiūnas, E., Šerpytis, P., & Laucevičius, A. (2021) · Medicina · doi:10.3390/medicina57070662 · Cited by 9
Editorial comment: Renal denervation
Schmieder, R. E., & Bosch, A. (2021) · Hypertension Research · doi:10.1038/s41440-021-00808-w · Cited by 8
Self-citationRader, F., Kirtane, A. J., Wang, Y. L., Daemen, J., Lurz, P. C., Sayer, J., Saxena, M., Levy, T., Azizi, M., & Weber, M. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.1222 · Cited by 3 · cited 1×
“In the presentation from RADIANCE-HTN SOLO 2-year follow-up [53], no adverse safety signals were observed.”
MethodSharp, A. S. P., Tunev, S. S., Schlaich, M. P., Lee, D. P., Finn, A. V., Trudel, J., & Kandzari, D. E. (2021) · Hypertension · doi:10.1161/hyp.78.suppl_1.p195 · Cited by 1
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Self-citationHypertension in chronic kidney disease—treatment standard 2023
Georgianos, P. I., & Agarwal, R. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad118 · Cited by 116
Diagnosis and management of resistant hypertension
Schiffrin, E. L., & Fisher, N. D. L. (2024) · BMJ · doi:10.1136/bmj-2023-079108 · Cited by 81
Sympathetic Nervous System and Atherosclerosis
Wang, Y., Anesi, J., Maier, M. C., Myers, M. A., Oqueli, E., Sobey, C. G., Drummond, G. R., & Denton, K. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713132 · Cited by 54
Renal nerves in physiology, pathophysiology and interoception
Evans, L. C., Dayton, A., & Osborn, J. W. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00893-3 · Cited by 46
“119), the efficacy of this approach in patients with kidney failure is difficult to discern.”
Metadata
- Authors
- Schmieder, R. E.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Corresponding author
- Schmieder, Roland E
- ORCID
- Schmieder, Roland E
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-05-25
- Volume
- 38
- Issue
- 5
- Pages
- 1089-1096
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC10157753
- OpenAlex
- W4281568867
- Cited by
- 39
- References
- 65
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 6 · 2023: 10 · 2022: 1
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nephrology Dialysis Transplantation (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Medtronic
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal and Vascular Pathologies
- Keywords
- renal denervation, chronic kidney disease, hypertension, catheter ablation, sympathetic hyperactivity, renal protection, adjunctive therapy, antihypertensive therapy
- MeSH terms
- Antihypertensive Agents, Blood Pressure, Denervation, Humans, Hypertension, Kidney, Sympathectomy, Treatment Outcome, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.